Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences commercializes FDA-approved sexual and reproductive health products for women’s health. Its product portfolio includes PHEXX® (lactic acid, citric acid and potassium bitartrate), a hormone-free contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, an oral antibiotic for bacterial vaginosis and trichomoniasis.
Company news commonly covers product sales, operating results, commercialization partnerships, distribution agreements and international regulatory activity for PHEXX and SOLOSEC. Updates also include manufacturing and supply arrangements, stockholder votes, capital-market actions and education or advocacy initiatives tied to women’s health communication.
Evofem Biosciences (NASDAQ: EVFM) issued a letter to stockholders detailing key achievements and future plans for 2020. Highlights include FDA approval of Phexxi, a non-hormonal contraceptive, and plans for its commercial launch in September. Evofem is also preparing for a Phase 3 trial for EVO100 aimed at preventing chlamydia and gonorrhea. The company raised approximately $136 million recently, strengthening its financial position. Despite challenges, Evofem remains focused on addressing unmet needs in women's health and driving stockholder value.